Key facts
- Notable investors include Vinno Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Libotek Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Libotek Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Libotek Biotechnology
Developer of genetic therapy technologies intended for treatment of neurodegenerative conditions. The company offers medical research, engineering development, and technical services with features such as gene diagnosis, therapeutic technology development, experimental animal resources, and consultation support, enabling the biotechnology and healthcare market to advance translational research, strengthen innovation capacity, and improve pathways for clinical applications through integrated scientific and technical expertise.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Libotek Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Libotek Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Libotek Biotechnology in its N-PORT filings yet. We sweep new filings monthly.